Asperlicin

Asperlicin
Nazivi
	IUPAC naziv (S-(2α,9β,9(R*),9α,β))-6,7-Dihydro-7-((2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo(1,2-a)indol-9-yl)methyl)quinazolino(3,2-a)(1,4)benzodiazepine-5,13-dione
Identifikacija
CAS broj	93413-04-8;
3D model (Jmol)	interaktivna slika;
PubChem C ID	3035433;
	SMILES CC(C)C[C@H]1C(=O)N2[C@H](N1)[C@@](C3=CC=CC=C32)(C[C@H]4C5=NC6=CC=CC=C6C(=O)N5C7=CC=CC=C7C(=O)N4)O; ; ; ; ; ;
Svojstva
Hemijska formula	C31H29N5O4
Molarna masa	535,593
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

Asperlicin je mikotoksin, izveden ih funguss Aspergillus alliaceus. On deluje kao selektivni antagonist holecistokininskog receptora CCK_A.^[3]^[4]^[5] On je bio vodeće jedinjenje za razvoj brojnih novih CCK_A antagonista sa mogućim kliničkim primenama.^[6]^[7]^[8]^[9]

Reference

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Chang, R. S.; Lotti, V. J.; Monaghan, R. L.; Birnbaum, J.; Stapley, E. O.; Goetz, M. A.; Albers-Schönberg, G.; Patchett, A. A.; Liesch, J. M.; Hensens, O. D.; Springer, James P. (1985). „A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus”. Science. 2994227 (4722): 177—179. Bibcode:1985Sci...230..177C. PMID 2994227. doi:10.1126/science.2994227.
^ Goetz, M. A.; Lopez, M.; Monaghan, R. L.; Chang, R. S.; Lotti, V. J.; Chen, T. B. (1985). „Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties”. The Journal of Antibiotics. 3005212 (12): 1633—1637. PMID 3005212. doi:10.7164/antibiotics.38.1633.
^ Liesch, J. M.; Hensens, O. D.; Springer, J. P.; Chang, R. S.; Lotti, V. J. (1985). „Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Structure elucidation”. The Journal of Antibiotics. 3841533 (12): 1638—1641. PMID 3841533. doi:10.7164/antibiotics.38.1638.
^ Bock, M. G.; Dipardo, R. M.; Rittle, K. E.; Evans, B. E.; Freidinger, R. M.; Veber, D. F.; Chang, R. S.; Chen, T. B.; Keegan, M. E.; Lotti, V. J. (1986). „Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility”. Journal of Medicinal Chemistry. 3761313 (10): 1941—1945. PMID 3761313. doi:10.1021/jm00160a024.
^ Evans, B. E.; Rittle, K. E.; Bock, M. G.; Dipardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Gould, N. P.; Lundell, G. F.; Homnick, C. F.; Veber, D. F. (1987). „Design of nonpeptidal ligands for a peptide receptor: Cholecystokinin antagonists”. Journal of Medicinal Chemistry. 2885419 (7): 1229—1239. PMID 2885419. doi:10.1021/jm00390a019.
^ Van Der Bent, A.; Ter Laak, A. M.; Ijzerman, A. P.; Soudijn, W. (1992). „Molecular modelling of asperlicin derived cholecystokinin a receptor antagonists”. European Journal of Pharmacology. 226 (4): 327—334. PMID 1397061. doi:10.1016/0922-4106(92)90050-6.
^ Lattmann, E.; Billington, D. C.; Poyner, D. R.; Howitt, S. B.; Offel, M. (2001). „Synthesis and evaluation of asperlicin analogues as non-peptidal cholecystokinin-antagonists”. Drug Design and Discovery. 11469752 (3): 219—230. PMID 11469752.

Spoljašnje veze

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Chang, R. S.; Lotti, V. J.; Monaghan, R. L.; Birnbaum, J.; Stapley, E. O.; Goetz, M. A.; Albers-Schönberg, G.; Patchett, A. A.; Liesch, J. M.; Hensens, O. D.; Springer, James P. (1985). „A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus”. Science. 2994227 (4722): 177—179. Bibcode:1985Sci...230..177C. PMID 2994227. doi:10.1126/science.2994227.

[4] Goetz, M. A.; Lopez, M.; Monaghan, R. L.; Chang, R. S.; Lotti, V. J.; Chen, T. B. (1985). „Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties”. The Journal of Antibiotics. 3005212 (12): 1633—1637. PMID 3005212. doi:10.7164/antibiotics.38.1633.

[5] Liesch, J. M.; Hensens, O. D.; Springer, J. P.; Chang, R. S.; Lotti, V. J. (1985). „Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Structure elucidation”. The Journal of Antibiotics. 3841533 (12): 1638—1641. PMID 3841533. doi:10.7164/antibiotics.38.1638.

[6] Bock, M. G.; Dipardo, R. M.; Rittle, K. E.; Evans, B. E.; Freidinger, R. M.; Veber, D. F.; Chang, R. S.; Chen, T. B.; Keegan, M. E.; Lotti, V. J. (1986). „Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility”. Journal of Medicinal Chemistry. 3761313 (10): 1941—1945. PMID 3761313. doi:10.1021/jm00160a024.

[7] Evans, B. E.; Rittle, K. E.; Bock, M. G.; Dipardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Gould, N. P.; Lundell, G. F.; Homnick, C. F.; Veber, D. F. (1987). „Design of nonpeptidal ligands for a peptide receptor: Cholecystokinin antagonists”. Journal of Medicinal Chemistry. 2885419 (7): 1229—1239. PMID 2885419. doi:10.1021/jm00390a019.

[8] Van Der Bent, A.; Ter Laak, A. M.; Ijzerman, A. P.; Soudijn, W. (1992). „Molecular modelling of asperlicin derived cholecystokinin a receptor antagonists”. European Journal of Pharmacology. 226 (4): 327—334. PMID 1397061. doi:10.1016/0922-4106(92)90050-6.

[9] Lattmann, E.; Billington, D. C.; Poyner, D. R.; Howitt, S. B.; Offel, M. (2001). „Synthesis and evaluation of asperlicin analogues as non-peptidal cholecystokinin-antagonists”. Drug Design and Discovery. 11469752 (3): 219—230. PMID 11469752.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]